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 INTRODUCTION
 Th e current obesity epidemic in children is paralleled by an 
increasing prevalence of nonalcoholic fatty liver disease (NAFLD), 
a condition characterized by early hepatic steatosis and by a more 
severe form known as nonalcoholic steatohepatitis (NASH). Key 
histologic components of NASH are steatosis, infl ammation, 
and hepatocellular ballooning ( 1 ). Children with biopsy-proven 
NAFLD were followed up for 20 years and demonstrated a shorter 
long-term survival. Some children evolved toward advanced 
fi brosis, others to cirrhosis, and a 20-year-old girl needed a liver 
transplantation owing to end-stage liver disease, hereby show-
ing the progressive nature of NAFLD even in young individuals 
( 2 ). Th erefore, as NASH progresses to these more severe chronic 
liver conditions, its early detection is crucial to design adequate 
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patient management and to reduce end-stage liver disease and 
overall mortality. Unfortunately, NASH cannot be identifi ed 
without pursuing a liver biopsy, the reference standard for accu-
rate staging and grading of NAFLD. Owing to the invasiveness 
of this method, the high costs, the level of discomfort, sampling 
error, and its risk for complications such as hemorrhage and bile 
peritonitis ( 3 ), liver biopsies, especially at a young age, should be 
replaced with noninvasive markers to detect NASH.
 In addition to plasma alanine aminotransferase (ALT), a num-
ber of functionally diverse biomolecules could be used as potential 
markers for pediatric NASH, including several proteins that change 
their expression and stability during the development of steatosis, 
infl ammation, and ballooning ( 4 ). An extensively studied molecule 
is the caspase-cleaved cytokeratin-18 (CK-18) that, in addition to 
its ability to detect hepatocellular apoptosis, is also able to distin-
guish NASH from simple steatosis in both adults and children ( 5,6 ).
 Previously, we demonstrated a clear and direct association 
between hepatic infl ammation and lysosomal cholesterol accumu-
lation inside Kupff er cells (KCs) of low-density lipoprotein recep-
tor knockout ( Ldlr−/− ) mice fed a high-fat, high-cholesterol diet 
( 7–9 ). In line with our observation in mice, cholesterol-containing 
KCs were also demonstrated recently in livers of NASH patients 
( 10 ). Further studies have shown that lysosomal cholesterol accu-
mulation induces disturbances in lysosomal (enzyme) traffi  ck-
ing ( 11,12 ). In particular, cathepsins, the main class of lysosomal 
proteases, have been described to have an early role in infl amma-
tion ( 13 ). In line, recent evidence showed a disruption of hepatic 
cathepsin expression in NAFLD patients ( 14 ).
 We hypothesized that cathepsin D (CatD) levels in plasma may 
be altered in subjects with NASH compared with subjects without 
NASH (i.e., steatosis). Th erefore, the aim of this study was to assess 
plasma levels of CatD in children with diff erent stages of NAFLD 
and to correlate these to histological criteria used for the diagno-
sis of NASH. In addition, receiver operating characteristic (ROC) 
curves were plotted to test the diagnostic accuracy of CatD.
 METHODS
 Sample collection for this study was performed at Hepato-Met-
abolic Department of Bambino Gesù Children’s Hospital during 
the period September 2012–December 2013. Th e study design 
conformed to the ethical guidelines of the Declaration of Helsinki 
(1975) and was performed according to the recommendations of 
the Ethics Committee of the Hospital.
 We included consecutive children aged 3 to 12 years with 
an ultrasonographic diagnosis of NAFLD and persistently (≥6 
months) elevated serum aminotransferases. Th e decision to biopsy 
NAFLD children was based on our previously published data, 
demonstrating a high prevalence of necroinfl ammatory changes 
and fi brosis in children with ultrasonographic steatosis and per-
sistently elevated liver enzymes ( 15 ). Blood samples were obtained 
just before the ultrasound-guided liver biopsy. All blood samples 
were originally processed to yield plasma and stored at −80 °C. 
Exclusion criteria were hepatic virus infections (hepatitis A, B, C, 
cytomegalovirus, and Epstein–Barr virus), type 1 diabetes mel-
litus, excessive alcohol consumption (≥140 g/week), history of 
parenteral nutrition, and use of drugs known to induce steato-
sis (e.g., valproate, amiodarone, or prednisone) or to aff ect body 
weight and carbohydrate metabolism. Autoimmune liver disease, 
metabolic liver disease, Wilson’s disease, celiac disease, type 2 dia-
betes mellitus, and α -1-antitrypsin defi ciency were ruled out using 
standard clinical, laboratory, and histological criteria ( 16,17 ).
 Liver histology
 Th e clinical indication for liver biopsy was either to assess and 
better defi ne the presence of NASH and the degree of fi brosis 
or to exclude other likely liver diseases ( 16 ). A Sonoline Omnia 
ultrasound machine (Siemens, Munich, Germany) equipped with 
a 5-MHz probe (5.0C50, Siemens) and a biopsy adaptor was used.
 Th e liver specimens of ≥15 mm length including at least 5–6 
complete portal tracts were considered adequate for the purpose 
of the study. Biopsies were routinely processed (i.e., formalin-
fi xed and paraffi  n-embedded) and sections of liver tissue were 
stained with hematoxylin–eosin, Van Gieson, periodic acid–Schiff  
diastase, and Prussian blue stain. Biopsies were evaluated by a 
single expert hepatopathologist who was unaware of the patient’s 
clinical and laboratory data. To determine the intraobserver agree-
ment, the pathologist scored the liver biopsies blindly twice, and 
the weighted κ -coeffi  cients for diff erent histological features were 
calculated.
 Th e main histological features of NAFLD/NASH, including 
steatosis, infl ammation, hepatocellular ballooning, and fi brosis, 
were scored using the NAFLD Clinical Research Network criteria 
( 18 ). Briefl y, steatosis was graded on a 4-point scale: grade 0=stea-
tosis involving <5% of hepatocytes; grade 1=steatosis involving 
up to 33% of hepatocytes; grade 2=steatosis involving 34–65% of 
hepatocytes; and grade 3=steatosis involving ≥66% of hepatocytes. 
Lobular infl ammation was graded on a 4-point scale: grade 0=no 
foci; grade 1=<2 foci per 200× fi eld; grade 2=2–4 foci per 200× 
fi eld; and grade 3=>4 foci per 200× fi eld. Hepatocellular balloon-
ing was graded from 0 to 2: 0=none; 1=few balloon cells; and 2 
=many/prominent balloon cells. Th e stage of fi brosis was quanti-
fi ed using a 5-point scale: stage 0=no fi brosis; stage 1=perisinusoi-
dal or periportal (1a=mild, zone 3, perisinusoidal; 1b=moderate, 
zone 3, perisinusoidal; 1c=portal/periportal); stage 2=perisinusoi-
dal and portal/periportal; stage 3=bringing; and stage 4=cirrhosis. 
Features of steatosis, lobular infl ammation, and hepatocellular bal-
looning were combined to obtain the NAFLD activity score (NAS 
score). Th e NAS score ranged from 1 to 7. As recently recom-
mended by NASH Clinical Research Network ( 19 ), a microscopic 
diagnosis based on overall injury pattern (steatosis, hepatocellular 
ballooning, infl ammation), as well as the presence of additional 
lesions (e.g., zonality of lesions, portal infl ammation, and fi brosis), 
has been assigned to each case. Accordingly, biopsies were subdi-
vided into steatosis, borderline NASH, and defi nite NASH ( 19 ).
 Laboratory assessment
 At the time of the liver biopsy, blood was taken for further analy-
sis. In all patients enrolled in this study, aspartate aminotrans-
ferase (AST), ALT, γ -glutamyl transpeptidase, triglycerides, total 
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cholesterol, albumin levels, glucose tolerance, and prothrombin 
time (international normalized ratio) were evaluated using stand-
ard laboratory methods. Insulin resistance was calculated accord-
ing to the Homeostatic Model Assessment-Insulin Resistance 
derived from basal values of glucose and insulin, as previously 
described ( 20 ).
 Human CatD enzyme-linked immunosorbent assay
 Plasma samples were diluted and CatD levels were determined by 
the CatD enzyme-linked immunosorbent assay according to the 
manufacturer’s protocol (Uscn Life Science, Wuhan, China). Th e 
absorbance was measured on a Benchmark 550 microplate reader 
(Bio-Rad, Hercules, CA). Th e detection limit ranges approxi-
mately from 46.88 to 3,000 pg/ml. Coeffi  cients of variation for 
intra- and inter-assays are <10 and <12%, respectively. Th e CatD 
measurements were performed blinded to the histology fi ndings 
of the study participants.
 CK-18 level measurements
 Part of plasma samples were used for quantitative determination 
of CK-18 levels by the M30-Apoptosense ELISA kit (PEVIVA) 
purchased from Li Starfi sh (Milan, Italy). All assays were per-
formed in duplicate, and the absorbance was determined using a 
microplate reader (Molecular Bio-Rad, Milan, Italy).
 Statistical analysis
 Th e data were analyzed by performing one-way analysis of 
variance and  post hoc Tukey’s test. Th e data were expressed as 
mean±s.e.m. and considered signifi cant at  P <0.05. To evaluate the 
performance of plasma CatD, the sensitivity, specifi city, predic-
tive values, and area under the curve (AUC) were calculated using 
ROC curve analysis for the following diff erentiations: steatosis vs. 
NASH, borderline NASH vs. NASH, steatosis + borderline NASH 
vs. NASH and steatosis vs. borderline NASH + NASH. A statistical 
signifi cance between two AUCs was evaluated by computing the 
 , followed by calcu-
lating two-tailed  P values.  P <0.05 was considered signifi cant. 
Th e analysis and the graphs were performed using GraphPad 
Prism 5 (version 5.03, GraphPad Soft ware Inc., San Diego, CA).
 To assess the diagnostic accuracy of the combination of CK-18 
with CatD, a logistic regression was fi tted to steatosis, borderline 
NASH, and NASH patients for both CK-18 and CatD. Statistical 
ROC analyses and AUC presented for the combination of CK-18 
with CatD were performed using the freely available program R ( 21 ) 
and the publicly available libraries “gnlm” ( 22 ) and “DiagnosisMed.”
 RESULTS
 General characteristics of the pediatric population
 A total of 96 children (mean age: 8.9 years, ranging from 3.3 to 
12.1 years) with NAFLD were enrolled in the study. Of these 96 
children, 56 were boys and 40 were girls with a mean age of 9.3 
and 8.4 years, respectively. NASH was diagnosed in 27% (26 sub-
jects) of the study population, whereas 51 subjects (53%) were 
diagnosed with borderline NASH and 19 subjects (20%) with 
steatosis ( Table 1 ). All children were obese (body mass index 
>95th percentile), and no diff erence was observed in body mass 
index percentile and waist circumference percentile between 
children with steatosis, borderline NASH, or defi nite NASH 
( Table 2 ). No diff erences were found in insulin resistance, glucose 
tolerance, the lipid profi le, and coagulation profi le (as indicated 
by the homeostatic model assessment-insulin resistance, the per-
centage of subjects with impaired glucose tolerance, the levels of 
cholesterol, triglycerides, albumin and the international normal-
ized ratio). Liver-specifi c parameters including ALT, AST, and 
γ -glutamyl transpeptidase were similar between all the groups. In 
response to NAFLD severity, a gradual signifi cant decrease was 
detected for plasma CatD, a lysosomal protease (steatosis vs. bor-
derline NASH:  P =0.0017; steatosis vs. NASH:  P <0.0001; border-
line NASH vs. NASH:  P <0.0001). In contrast, CK-18 increased in 
response to NAFLD severity and could diff erentiate steatosis from 
borderline NASH ( P =0.0001) and NASH ( P =0.0003). No diff er-
ence in CK-18 levels was observed between borderline NASH and 
defi nite NASH ( P =0.95).
 Signifi cantly reduced levels of plasma CatD correlate with 
pediatric NAFLD disease severity
 First, we investigated whether plasma CatD levels correlated with 
histological features of NAFLD. We found that plasma levels of 
CatD decreased signifi cantly in parallel with the increasing degree 
 Table 1 .  Histological features of the pediatric subjects 
  Steatosis 
( n =19) 
 Borderline 
NASH ( n =51) 
 NASH ( n =26) 
 NAS  2.2±0.3  3.9±0.2  5.7±0.1 
 Steatosis (%) 
 5–33%  15 (78.9)  10 (19.6)  2 (7.7) 
 34–65%  3 (15.8)  5 (9.8)  5 (19.2) 
 ≥66%  1 (5.3)  36 (70.6)  19 (73.1) 
 Infl ammation (%) 
 Grade 0  5 (26.3)  1 (2.0)  0 
 Grade 1  13 (68.4)  33 (64.7)  12 (46.2) 
 Grade 2  1 (5.3)  17 (33.3)  14 (53.8) 
 Ballooning (%) 
 None  17 (89.5)  22 (43.1)  3 (11.5) 
 Few  1 (5.3)  24 (47.1)  15 (57.7) 
 Many  1 (5.3)  5 (9.8)  8 (30.8) 
 Fibrosis (%) 
 Stage 0  10 (52.6)  19 (37.3)  7 (26.9) 
 Stage 1  8 (42.1)  26 (51.0)  16 (61.5) 
 Stage 2  1 (5.3)  5 (9.8)  0 
 Stage 3  0  1 (2.0)  3 (11.5) 
 NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, 
nonalcoholic steatohepatitis. 
 NAS is represented as mean±s.e.m. 
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of NAFLD and the NAS score ( Figure 1 ). Furthermore, in line 
with the increased presence of hepatocellular ballooning, a key 
histological feature of NASH, plasma CatD declined. By examin-
ing the individual stages of NAFLD, we demonstrate that, unlike 
late-stage fi brosis, CatD was reduced upon increasing degrees of 
steatosis and infl ammation. Th us, plasma CatD was signifi cantly 
lowered in children with NASH compared with children with 
either steatosis or borderline NASH and was associated with early 
stages of NAFLD (i.e., steatosis and infl ammation).
 Plasma ALT does not correlate with the histological pattern of 
NAFLD in children
 Currently, plasma ALT is primarily used in the clinic as a nonin-
vasive marker to detect NASH. To make a comparison between 
CatD and ALT, plasma ALT levels were also measured. Opposite 
to CatD, a trend toward increasing ALT levels in parallel with 
increasing NAFLD severity was found ( Figure 2 ). However, this 
diff erence was not signifi cant, neither for Brunt’s nor Kleiner’s 
criteria. Unlike CatD, ALT levels remained similar upon severe 
degrees of hepatocellular ballooning and steatosis. ALT levels 
increased with increasing severity of infl ammation, but did not 
reach a statistically signifi cant level. During fi brosis, a trend 
toward an increase in ALT levels was found between patients who 
displayed no fi brosis and those who demonstrate mild or severe 
fi brosis. Altogether, ALT is not able to diff erentiate between the 
diff erent stages of pediatric NAFLD and is more associated with 
late-stage fi brosis.
 CK-18 can differentiate between steatosis and NASH and 
correlates with some histological features of pediatric NAFLD
 As previous research has shown that plasma levels of CK-18 are 
accurate in predicting NASH vs. no NASH in adults ( 5 ) and chil-
dren ( 6 ), we point to confi rm these data in our cohort. In this 
study, CK-18 was increased in pediatric subjects with borderline 
NASH and defi nite NASH compared with steatosis. However, 
CK-18 levels remained identical between children with borderline 
and defi nite NASH ( Figure 3 ). CK-18 was signifi cantly increased 
in subjects with a high NAS score (3–4 and 5–7) compared with 
children with an NAS score of 1–2. To determine whether there 
is an association between CK-18 and severity of NAFLD, we cat-
egorized CK-18 according to the histological stages of hepatocyte 
ballooning, steatosis, infl ammation, and fi brosis. In this cohort, 
CK-18 was signifi cantly increased upon MODERATE hepatocyte 
ballooning and increased along with the severity of steatosis and 
infl ammation. No diff erence in CK-18 levels between the diff er-
ent stages of fi brosis was observed. Altogether, we confi rm that 
 Table 2 .  Clinical characteristics of the pediatric population 
  P  value between groups 
  Steatosis (1) ( n =19)  Borderline NASH (2) ( n =51)  NASH (3) ( n =26)  1 vs. 2  1 vs. 3  2 vs. 3 
 Male (%)  12 (63.2)  29 (56.9)  15 (57.7)  0.886  0.930  0.997 
 Age (years)  10.0±0.5  8.4±0.3  9.2±0.4  0.016  0.378  0.314 
 Weight (kg)  52.0±2.6  45.2±2.2  44.3±2.0  0.155  0.149  0.958 
 Length (cm)  139.9±2.8  132.4±2.4  135.0±2.7  0.158  0.531  0.753 
 BMI percentile  96.0±0.8  96.0±0.7  96.1±0.8  1.000  0.995  0.996 
 WC percentile  83.6±2.4  77.9±1.4  82.9±1.7  0.079  0.973  0.084 
 Obese (%)  19 (100)  47 (92.2)  24 (92.3)  0.458  0.551  1.000 
 Cholesterol (mg/dl)  167.3±8.6  163.3±5.1  153.3±7.6  0.915  0.427  0.506 
 Triglycerides (mg/dl)  94.0±8.4  111.1±8.2  125.9±21.9  0.664  0.328  0.685 
 ALT (U/l)  61.6±7.4  83.7±5.6  91.0±15.3  0.258  0.152  0.830 
 AST (U/l)  46.7±3.5  55.3±2.6  57.4±7.2  0.387  0.311  0.929 
 GGT (U/l)  26.0±2.5  29.1±2.7  30.0±4.4  0.814  0.769  0.981 
 Cathepsin D (pg/ml)  32,658±3,640  21,428±1,753  8,095±784  0.002  <0.0001  <0.0001 
 CK-18 (U/l)  261.6±24.5  350.6±11.2  356.4±6.6  0.0001  0.0003  0.950 
 Albumin (g/dl)  4.5±0.1  4.5±0.1  4.6±0.1  0.866  0.668  0.869 
 INR  1.1±0.05  1.2±0.03  1.1±0.04  0.838  0.997  0.853 
 IGT (%)  0 (0)  9 (17.6)  4 (15.4)  0.137  0.297  0.959 
 HOMA-IR  2.7±0.4  2.5±0.3  2.4±0.3  0.973  0.922  0.970 
 ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CK-18, cytokeratin-18; GGT, γ -glutamyl transpeptidase; HOMA-IR, homeostasis 
model assessment of insulin resistance; IGT, impaired glucose tolerance; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis; WC, waist circumfer-
ence. 
 Data are represented as mean±s.e.m. Bold values signify  P <0.05. Data were statistically analyzed using one-way analysis of variance (ANOVA) tests using the SPSS 
software, version 22.0 (SPSS, Chicago, IL). 
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curves. For the comparison between steatosis and NASH, the ROC 
curve of CatD demonstrated a signifi cant higher AUC of 0.94 as 
compared with the AUC values of ALT (0.59;  P =0.0004) and CK-18 
(0.72;  P =0.0225;  Figure 4a and  Table 3 ). With regard to the diff er-
entiation between borderline NASH and defi nite NASH, an AUC 
value of 0.85 was reached by using CatD, and this was signifi cantly 
higher than the AUC values of ALT (0.57;  P =0.0011) and CK-18 
(0.57;  P =0.0003;  Figure 4b ). An AUC value of 0.88 for CatD was 
given for the diff erentiation between steatosis+borderline NASH 
vs. NASH, compared with an AUC of 0.52 and 0.53 for ALT and 
CK-18, respectively ( Figure 4c ). For this diff erentiation, further 
statistical analysis revealed that the AUC value of CatD is higher 
than the AUC values of ALT ( P <0.0001) and CK-18 ( P <0.0001; 
 Table 3 ). No signifi cant diff erences were observed between 
the AUCs of CatD (AUC: 0.81), ALT (AUC: 0.66), and CK-18 
(AUC: 0.74) to distinguish steatosis vs. borderline NASH+NASH 
( Figure 4d and  Table 3 ).
 Th e diagnostic performances of CatD, ALT, and CK-18 in the 
prediction of NASH are depicted in  Supplementary Table S1 
online. Th e best cutoff  point for CatD was <18,445 pg/ml, dem-
onstrating the highest sensitivity (100%) and specifi city (89.5%). 
Positive and negative predictive values (PPV and NPV) were 
calculated and were 92.9% and 100%, respectively. In contrast to 
CatD, ALT and CK-18 displayed lower sensitivity and specifi city 
rates and less accurate PPV and NPV percentages to predict pedi-
atric NASH.
 In short, compared with ALT and CK-18, CatD holds better 
diagnostic value to predict pediatric NASH and is accurate in 
making the diff erentiation between pediatric NASH subjects from 
those who have steatosis. Similar to steatosis vs. NASH subjects, 
CatD also improves the prediction of NASH compared with the 
combination of steatosis+borderline NASH, and also compared 
with borderline NASH separately.
CK-18 is able to distinguish NASH from steatosis in children with 
NAFLD.
 Plasma CatD holds a better predictive value for the differentiation 
between steatosis and NASH in children than CK-18 and ALT
 We next investigated the clinical potential of plasma CatD for 




































































 Figure 1 .  Cathepsin D in plasma of pediatric nonalcoholic fatty liver 
disease (NAFLD) subjects. Cathepsin D levels were analyzed in children 
with NAFLD divided by biopsy-proven steatosis, borderline nonalcoholic 
steatohepatitis (NASH), and NASH (light-grey bars) or divided upon the 
NAS score (dark-grey bars). The colored bars show plasma cathepsin D 
for the individual stages of NAFLD. Classifi cation  Mild indicates a stage 
0 for hepatocellular ballooning, stage 1 for steatosis, and stage 0 for 
infl ammation and fi brosis. Classifi cation  Moderate indicates stage 1 for 
hepatocellular ballooning, stage 2 for steatosis, and stage 1 for infl amma-
tion and fi brosis. Classifi cation  Severe indicates stage 2 for hepatocellular 
ballooning, stage 3 for steatosis, stage 2 for infl ammation, and stage 2+3 
for fi brosis. Asterisks denote signifi cance compared with the correspond-
ing fi rst (left) bar for each classifi cation. Each classifi cation is indicated by 
the light-grey, the dark-grey, and the colored bars. * P <0.05, ** P <0.01, 
and *** P <0.001. The hashtag (#) notation represents signifi cance com-
pared with the corresponding second (middle bar) for each classifi cation. 





















































 Figure 2 .  Plasma alanine aminotransferase (ALT) levels in children with 
biopsy-proven nonalcoholic fatty liver disease (NAFLD). ALT levels in chil-
dren with NAFLD divided by biopsy-proven steatosis, borderline nonalco-
holic steatohepatitis (NASH), and NASH (light-grey bars) or divided upon 
the NAS score (dark-grey bars). The colored bars show plasma ALT for the 























































 Figure 3 .  Cytokeratin-18 (CK-18) levels in plasma of children with non-
alcoholic fatty liver disease (NAFLD). CK-18 measurements were plotted 
against the several stages of NAFLD. Asterisks denote signifi cance com-
pared with the corresponding fi rst (left) bar for each classifi cation. Each 
classifi cation is indicated by the light-grey, the dark-grey, and the colored 
bars. * P <0.05, ** P <0.01, and *** P <0.001. The hashtag (#) notation 
represents signifi cance compared with the corresponding second (middle 
bar) for each classifi cation.  # P <0.001. NAS, NAFLD activity score; NASH, 
nonalcoholic steatohepatitis.
 










Cathepsin D in Pediatric Hepatic Inflammation
 Adding CK-18 to CatD improves the diagnostic accuracy to 
predict pediatric NASH
 To explore whether adding a liver-specifi c marker, CK-18, to CatD 
would lead to a better prediction of pediatric NASH, we plotted 
ROC curves of CatD combined with CK-18. Whereas CatD alone 
demonstrated an AUC of 0.94 for the comparison of steatotic 
subjects vs. patients with NASH ( Figure 4a ), the combination 
of CK-18 with CatD resulted in an AUC of 0.998 ( Figure 5a ). 
Compared with using CatD alone, combining CK-18 with CatD 
did not increase the AUC values for the diff erentiations border-
line NASH vs. NASH, and steatosis+borderline NASH vs. NASH 
( Figures 4b,c and 5b,c ). When distinguishing steatosis from 
borderline NASH+NASH patients by using CatD individually, an 
AUC value of 0.81 was reached ( Figure 4d ). Upon the addition 
of CK-18, an AUC value of 0.85 was obtained ( Figure 5d ). Th ese 
data illustrate that adding CK-18 to CatD contributes to reaching 
an optimal ROC curve for the diagnostic prediction of pediatric 
steatosis vs. NASH.
 DISCUSSION
 Diagnosing NASH during childhood is of critical importance to 
prevent further progression into NAFLD-related cirrhosis and 
end-stage liver disease during adolescence. Th erefore, under-
standing the mechanisms that cause progression to NASH at an 
early age is crucial.
 With the help of lysosomal enzymes, lysosomes are best known 
for their primary role in protein degradation. However, lysosomal 
function is not merely restricted to degradation of proteins, but 
increasing evidence now demonstrates that the lysosomal com-
partment also has a role in the immune system and can be seen as 
secretory vesicles ( 23,24 ). Numerous studies have shown that lyso-
somal cholesterol accumulation inside macrophages is an event 
that occurs during infl ammation and has been detected in NASH 
as well as in atherosclerosis ( 7,25 ). In line, cathepsins have been 
shown to be signifi cantly involved in mediating the infl ammatory 
response and cholesterol traffi  cking ( 13,26,27 ).
 Furthermore, it has been reported that cathepsin expression was 



























































Steatosis vs. borderline NASH + NASH
1.0
 Figure 4 .  The diagnostic value of cathepsin D, cytokeratin-18 (CK-18), and alanine aminotransferase (ALT) in pediatric nonalcoholic fatty liver disease 
(NAFLD). Receiver operating characteristic (ROC) curve analysis was performed to assess the area under the curve (AUC) of using plasma cathepsin D, 
CK-18, or ALT to predict hepatic infl ammation for the following comparisons: ( a ) steatosis vs. nonalcoholic steatohepatitis (NASH); ( b ) borderline NASH vs. 
NASH; ( c ) steatosis combined with borderline NASH vs. NASH; and ( d ) steatosis vs. borderline NASH+NASH.
 
 Table 3 .  Overview of the calculated  P values between the 
different AUCs 
  Cathepsin D 
vs. ALT 




 Steatosis vs. NASH  P =0.0004  P =0.0225  P =0.2840 
 Borderline NASH vs. NASH  P =0.001 1  P =0.0003  P =0.9629 
 Steatosis+borderline NASH 
vs. NASH 
 P <0.000 1  P <0.0001  P =0.9204 
 Steatosis vs. borderline 
NASH+NASH 
 P =0.1030  P =0.4299  P =0.4189 
 ALT, alanine aminotransferase; AUC, area under curve; CK-18, cytokeratin-18; 
NASH, nonalcoholic steatohepatitis.
 P values in bold indicate statistically signifi cant differences. 
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calcium-dependent process and has been shown to be sensitive for 
cholesterol levels. As a result, inducing lysosomal cholesterol accu-
mulation completely inhibited lysosomal exocytosis, suggesting that 
storage of lysosomal cholesterol has a crucial role in pediatric NASH 
( 30 ). Th ese data are in line with previous results showing high cho-
lesterol levels in KCs, as was indicated by numerous cholesterol-fi lled 
droplets in KCs of livers of NASH patients, whereas livers of steatotic 
patients did not show this typical foam cell-like phenotype ( 10 ). How-
ever, foam cell-like structures were so far only detected in NASH livers 
of adults, and still needs to be confi rmed in NASH livers of children.
 Excessive cholesterol inside lysosomes can also damage the 
lysosomal membrane and cause lysosomal membrane permea-
bilization. In turn, there is leakage of cathepsins into the cytosol, 
whereby cathepsins can mediate the apoptotic signaling path-
way ( 31 ). Th us, instead of extracellular secretion, less viable cells 
remain left  to secrete CatD because of increased apoptosis.
 Th e gold standard to diagnose pediatric NASH is still an invasive 
liver biopsy procedure. However, owing to its invasiveness, biop-
sies are not performed as a fi rst step. Th erefore, clinicians rely on 
several noninvasive methods to detect NASH in children, such as 
liver markers (ALT/AST) and imaging techniques (ultrasound, 
these proteins in the setting of liver infl ammation ( 14 ). In addition, 
these fi ndings would indicate that cathepsins are more likely to be 
involved during early stages of NAFLD, rather than a refl ection of a 
late consequence of infl ammation. Indeed, in this study, we showed 
that levels of plasma CatD are decreased at early stages of NASH, 
whereas these remain similar upon the diff erent stages of fi brosis. 
Th is was in contrast to plasma ALT that showed an increase dur-
ing late-stage fi brosis and was more representative for liver damage. 
Similarly, a correlation exists between circulating CatD and carotid 
intima–media thickness, an indicator of atherosclerosis ( 28 ). In line 
with these results, abnormal CatD fractions were associated with a 
lysosomal storage disease ( 29 ), a disease predominantly character-
ized by chronic systemic infl ammation. Th us, it seems that lysoso-
mal cholesterol accumulation in KCs, and its subsequent eff ect on 
lysosomal enzyme homeostasis, has a central role in the develop-
ment of childhood NASH. Although many evidences point to the 
link between lysosomal enzymes and NASH, the exact mechanisms 
that lead to the secretion of the lysosomal content in plasma are not 
yet known.
 Lysosomes are able to secrete their content, including lysosomal 





























































Steatosis vs. borderline NASH +NASH





 Figure 5 .  The diagnostic value of adding cytokeratin-18 (CK-18) to cathepsin D. Receiver operating characteristic (ROC) curve analysis was performed to 
assess the area under the curve (AUC) of using the combination of plasma CK-18 with cathepsin D to predict hepatic infl ammation for the following dif-
ferentiations: ( a ) steatosis vs. nonalcoholic steatohepatitis (NASH); ( b ) borderline NASH vs. NASH; ( c ) steatosis combined with borderline NASH vs. NASH; 
and ( d ) steatosis vs. borderline NASH+NASH.
 










Cathepsin D in Pediatric Hepatic Inflammation
computed tomography scan and magnetic resonance imag-
ing). Currently, ALT is the primary clinical parameter to evalu-
ate NAFLD in children. However, by using a biopsy-confi rmed 
NAFLD cohort, it was found that AST and ALT have limited pre-
dictive power to discriminate between low and high NAS scores 
in children, with AUC values varying from 0.59 to 0.76 ( 32 ). In 
line, normal ALT levels were observed despite the presence of 
NAFLD, confi rming a low correlation between ALT and NAFLD 
( 33 ). Th ese data are confi rmed in our study by demonstrating low 
AUC (0.53–0.59) and predictive values (PPV: 72.7% and NPV: 
56.5%) for ALT in the discrimination between NASH and no 
NASH.
 A promising serum marker in adults is CK-18 that is repre-
sentative of hepatocyte apoptosis. Recently, CK-18 was tested in 
a biopsy-proven children cohort, confi rming that CK-18 is also 
an accurate way of predicting NASH vs. steatosis already during 
early life ( 34 ). Similarly, a second pediatric study confi rmed the 
high diagnostic accuracy for CK-18 in predicting NASH (AUC 
value: 0.93) and a PPV and NPV of 94% and 72%, respectively 
( 6 ). Comparable to these studies, we now found a high AUC value 
(0.72) and similar PPV and NPV values of CK-18 (72% and 100%, 
respectively) for the detection of NASH vs. steatosis, confi rming 
that CK-18 is accurate at diagnosing NASH in children. How-
ever, in our cohort, plasma CatD correlated better with pediatric 
NAFLD disease progression than CK-18. Altogether, in contrast 
to other plasma parameters tested for pediatric NASH, our data 
suggest that plasma CatD is a highly accurate and early nonin-
vasive marker to distinguish steatosis vs. NASH in children. In 
contrast to CK-18, CatD correlated signifi cantly with NAFLD 
severity.
 Despite our signifi cant fi ndings, the cohort that was used is 
relatively small in patient size and is of cross-sectional nature. 
Additional cohorts and future longitudinal studies are essential to 
validate plasma CatD as a useful tool to detect pediatric hepatic 
infl ammation. Moreover, in view of statistics, a larger sample size 
would also boost the statistical power. Furthermore, intervention 
studies should be performed to test whether plasma CatD could 
be implicated in the clinical follow-up. As obtaining liver biopsies 
from children with normal aminotransferases is rarely performed, 
all pediatric individuals in this study demonstrate abnormal ami-
notransferase levels. As such, children with normal levels of ami-
notransferases are not included, and, consequently, the level of 
plasma CatD under healthy conditions is not known. Th e same 
restriction holds true for studying CatD in relation to NAFLD in 
children or adults with a normal body mass index.
 Altogether, in this study, we used a well-defi ned biopsy-proven 
population of children and evaluated plasma levels of CatD. We 
have demonstrated for the fi rst time that plasma CatD is signifi -
cantly decreased in children with NASH compared with children 
with either steatosis or borderline NASH. Plasma CatD holds high 
diagnostic value and could be used as a promising noninvasive 
clinical marker to distinguish pediatric NASH patients from sub-
jects with steatosis, especially upon the addition of CK-18. Fur-
thermore, this is the fi rst human study to show that the lysosomal 
compartment changes under infl ammatory conditions. However, 
future research is warranted to fully understand the novel role 
of lysosomes during the development of early NASH. Moreover, 
whether CatD can be used in clinical practice as a noninvasive 
marker for NASH should be validated in additional larger well-
defi ned NAFLD cohorts in children and adults.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  As noninvasive tools are lacking, the current gold standard 
to diagnose hepatic infl ammation in children is an invasive 
liver biopsy. 
 ✓  Previous  in vivo studies revealed an association between 
lysosomal cholesterol accumulation in Kupffer cells and 
hepatic infl ammation. 
 WHAT IS NEW HERE 
 ✓  Cathepsin D levels in plasma are signifi cantly reduced in 
children with biopsy-proven liver infl ammation compared to 
those who have steatosis. 
 ✓  Plasma cathepsin D correlated with pediatric nonalcoholic 
fatty liver disease (NAFLD) progression better than current 
noninvasive markers. 
 ✓  Cathepsin D holds a high predictive value and has the 
potential to improve noninvasive diagnosis of hepatic 
infl ammation in children. 
 ✓  Plasma lysosomal enzymes play an important role during 
pediatric liver infl ammation. 
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